A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Some assume pneumonia is an inevitable consequence of ageing, while others may not realise they are at risk, says infectious ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

The Allan Labor Government is backing a new study to boost the number of expectant mothers having the Respiratory Syncytial Virus (RSV) immunisation ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

The global at-home testing market is poised for remarkable growth, with sales projected to rise from USD 7,789.1 million in 2025 to USD 11,877.8 million by 2035, according to recent market analysis.

Roughly 8000 Brits died from respiratory syncytial virus infections last year, with tens of thousands likely clogging up ...